Active Ingredient: Mitomycin
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
5 - 10 mg per m² of body surface area (BSA)
From 5 To 10 mg per m² of body surface area (BSA) once every 14 day(s)
In cytostatic monochemotherapy mitomycin is usually administered intravenously as a bolus injection. The recommended dosage is 5-10 mg/m² of body surface every 1-6 weeks, depending on the therapeutic scheme used.
A dose greater than 20 mg/m² gives more toxic manifestations without therapeutic benefits. The maximum cumulative dose of mitomycin is 60 mg/m².
In combination therapy the dosage is considerably lower. Because of the risk of additive myelotoxicity, proven treatment protocols may not be deviated from without a specific reason.
Bolus injection.
Intravenous
10 - 20 mg per m² of body surface area (BSA)
From 10 To 20 mg per m² of body surface area (BSA) once every 42 day(s)
In cytostatic monochemotherapy mitomycin is usually administered intravenously as a bolus injection. The recommended dosage is 10-20 mg/m² of body surface every 6-8 weeks, depending on the therapeutic scheme used.
A dose greater than 20 mg/m² gives more toxic manifestations without therapeutic benefits. The maximum cumulative dose of mitomycin is 60 mg/m².
In combination therapy the dosage is considerably lower. Because of the risk of additive myelotoxicity, proven treatment protocols may not be deviated from without a specific reason.
Bolus injection.
Intravenous
8 - 12 mg per m² of body surface area (BSA)
From 8 To 12 mg per m² of body surface area (BSA) once every 28 day(s)
In cytostatic monochemotherapy mitomycin is usually administered intravenously as a bolus injection. The recommended dosage is 8-12 mg/m² of body surface every 3-4 weeks, depending on the therapeutic scheme used.
A dose greater than 20 mg/m² gives more toxic manifestations without therapeutic benefits. The maximum cumulative dose of mitomycin is 60 mg/m².
In combination therapy the dosage is considerably lower. Because of the risk of additive myelotoxicity, proven treatment protocols may not be deviated from without a specific reason.
Bolus injection.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
